There is a growing body of evidence suggesting possible therapeutic role of statin medications on advanced prostate cancer outcomes. However, little is known regarding the impact of the type of statin medications used, the dose of statins received, or the duration of treatment with this class of medications on PCa outcomes. Our goal was to investigate the impact of the statin type, dose and duration on oncologic outcomes in patients with advanced prostate cancer who are treated with androgen deprivation therapy (ADT).
INTRODUCTION AND OBJECTIVES:
There is a growing body of evidence suggesting possible therapeutic role of statin medications on advanced prostate cancer outcomes. However, little is known regarding the impact of the type of statin medications used, the dose of statins received, or the duration of treatment with this class of medications on PCa outcomes. Our goal was to investigate the impact of the statin type, dose and duration on oncologic outcomes in patients with advanced prostate cancer who are treated with androgen deprivation therapy (ADT).
METHODS: We used the national VA database to identify all men diagnosed with PCa who are receiving ADT and were treated with statin medications for at least 6 months after PCa diagnosis between 2000 and 2008 with follow-up through May 2016. Patients were then stratified based on the type of statins (hydrophilic vs. lipophilic), the cumulative dose of statins (based on WHO defined daily dose for each statin medication), and the total duration of statins use (< 12 months, 12-24 months, 24-36 months, and ! 36 months). Multivariable Cox proportional hazards analyses were performed to assess the association between cumulative duration, dose, and type of statin used and prostate cancer specific survival (PCSS), overall survival (OS) and skeletal related events (SREs).
RESULTS: A total of 53,582 PCa patients on ADT were included in the study cohort. The median patient age was 74 years and majority (65.7%) were Caucasian. Seventy-five percent of patients had Charlson co-morbidity index of 1. The median PSA at time of diagnosis was 9.6 ng/dl. On multivariable Cox proportional hazards analysis controlling for multiple baseline characteristics, increased duration > 36 months (HR 0.48, , a large real-world study of sipuleucel-T in men with mCRPC, offers an opportunity to examine patients who experienced longer term (!3 yr) survivals after receiving sipuleucel-T. The current analysis seeks insights regarding these patients, especially noting the timing of sipuleucel-T relative to the other FDA-approved treatments in the modern era.
METHODS: Men with mCRPC receiving sipuleucel-T, given every 2 weeks x 3, were eligible for PROCEED. Follow-up continued until death, study withdrawal, or a minimum of 3 years. Long-term survivors were defined as those who survived !3 yr. Baseline characteristics and treatments received pre/post-sipuleucel-T are reported in this ad-hoc subgroup analysis. RESULTS: From 2011 -2014 , 1902 men received !1 sipuleucel-T infusion. Of these, an estimated 42.3% survived !3yr. At baseline, long-term survivors (OS !3 yr) and those who survived <3 yr had no notable differences in laboratory measures or patterns of metastatic spread. Long-term survivors were less likely to have received OS-prolonging therapies (abiraterone, enzalutamide, docetaxel, or cabazitaxel) prior to sipuleucel-T, but received more lines of OS-prolonging therapies after sipuleucel-T, compared to those who survived < 3yr (median 2.0 v. 1.0).
CONCLUSIONS: In the modern era, a considerable number of patients with mCRPC survived !3 yr. These patients were more likely to have received sipuleucel-T as 1st-line therapy for mCRPC than those with survivals <3 yr. Long-term survivors also received more lines of agents known to improve OS in mCRPC after sipuleucel-T.
INTRODUCTION AND OBJECTIVES: Metabolic syndrome (MetS) is associated with an increased risk of aggressive prostate cancer (PCa). However, MetS
has not yet been included in the available nomograms used to predict the risk of high grade PCa. The aim of our study was to develop a clinical nomogram for the prediction of high grade PCa.
METHODS: A consecutive series of men undergoing prostate biopsies were enrolled in a single center. Indications for prostate biopsy included abnormal prostate specific antigen level (PSA>4ng/ml) and/or abnormal digital rectal examination (DRE). Patients with PSA 50ng/ml were excluded from the analysis. Demographic and clinical characteristics of the patients were recorded. Metabolic syndrome was defined according to the adult treatment panel III. A nomogram was generated based on the logistic regression model used to predict high grade prostate cancer defined as Epstein Gleason grade !3 (ISUP 2014).
RESULTS: Overall 762 patients were enrolled. Mean age was 68AE8 years, mean BMI was 27AE5.6 and mean PSA was 6.4AE6ng/ml. CONCLUSIONS: Metabolic syndrome is highly prevalent in patients at risk of prostate cancer and it increases the risk of high grade prostate cancer. Our nomogram offers the possibility to include metabolic status in the assessment of patients with prostate cancer to identify men who are at risk of high grade disease. External validation is warranted before its clinical implementation.
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PD25-08 BODY IMAGE ISSUES AND ATTITUDES TOWARDS EXERCISE IN MEN DIAGNOSED WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY
Caterina Gentili*, Stuart McClean, Lucy Hackshaw-McGeagh, Amit Bahl, Raj Persad, Diana Harcourt, Bristol, United Kingdom INTRODUCTION AND OBJECTIVES: Androgen Deprivation Therapy (ADT) is a well-established treatment for prostate cancer (PCa). ADT side effects can impact on body composition and functioning. Some patients might experience feelings of body feminization that can be detrimental to their body and appearance satisfaction. ADT side effects are well known, but only a limited amount of research explored their psychological impact on men's body image.
A potential strategy to counterbalance ADT side effects, promote mental health and reduce appearance-related concerns could be exercise. However, adherence to exercise recommendations is very low.
Therefore, this qualitative exploratory study aimed to:
• Explore the impact of ADT-induced appearance and functionality changes on patients' body image.
• Investigate patients' attitudes towards exercise and potential exercise barriers. METHODS: We conducted 22 semi-structured interviews with PCa patients following ADT (Mage [ 67.9 yo, SD [ 9.99 ). The interviews touched upon ADT-induced bodily changes, body image issues, and exercise. Each interview lasted around 45 minutes, was audio-recorded and transcribed word-by-word. Thematic content analysis was conducted with NVivo.
RESULTS: We extracted 4 main themes and 14 sub-themes. 1) Body Image concept. For some patients body image concerns represented either a novel topic or a problem they never felt able to talk about. Body image was also often conceived as "what other people can see" rather than one's judging of his own body.
2) Bodily changes. Participants expressed appearance dissatisfaction focusing on body feminization. In particular, breasts enlargement, weight gain, functionality loss, and sexual issues had an impact on their sense of masculinity.
3) Exercise benefits. Participants reported to exercise to counterbalance ADT side effects, weight gain in particular. Moreover, exercise gave them a sense of achievement and control over their bodies despite cancer, and a renovated sense of physical self-efficacy.
